Vivo Capital IX, LLC
CIK 0001750698 Name as filed on the most recent filing
Filed as Vivo Capital IX, LLC (11)
17 transaction lines · from 11 filings · filed 2020-07-21 to 2023-08-10 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
- ISSUER IO Biotech, Inc. 2 filings
- ISSUER Tarsus Pharmaceuticals, Inc. 6 filings
- ISSUER Sierra Oncology, Inc. 1 filings
- ISSUER Instil Bio, Inc. 1 filings
- ISSUER ALX Oncology Holdings Inc 1 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2023-08-09 |
IO Biotech, Inc. IOBT |
P, Open-market purchase | 3,157,894 acquired | 1.90 | 5,999,998.60 | Form 4, filing 0001213900-23-065297 | |
| 2022-05-05 |
Tarsus Pharmaceuticals, Inc. TARS |
S, Open-market sale | 5,374 disposed | 12.25 | 65,831.50 | Form 4, filing 0001213900-22-024317 | |
| 2022-05-04 |
Tarsus Pharmaceuticals, Inc. TARS |
S, Open-market sale | 19,738 disposed | 12.67 | 250,080.46 | Form 4, filing 0001213900-22-024052 | |
| 2022-05-03 |
Tarsus Pharmaceuticals, Inc. TARS |
S, Open-market sale | 451,418 disposed | 13.25 | 5,981,288.50 | Form 4, filing 0001213900-22-024052 | |
| 2022-05-02 |
Tarsus Pharmaceuticals, Inc. TARS |
S, Open-market sale | 41,800 disposed | 15.19 | 634,942.00 | Form 4, filing 0001213900-22-024052 | |
| 2022-01-31 |
Sierra Oncology, Inc. SRRA |
P, Open-market purchase | 800,000 acquired | 27.00 | 21,600,000.00 | Form 4, filing 0001213900-22-004647 | |
| 2021-11-09 |
IO Biotech, Inc. IOBT |
P, Open-market purchase | 650,000 acquired | 14.00 | 9,100,000.00 | Form 4, filing 0001140361-21-037658 | |
| 2021-06-25 |
Tarsus Pharmaceuticals, Inc. TARS |
S, Open-market sale | 7,704 disposed | 29.60 | 228,038.40 | Form 4, filing 0001213900-21-034310 | |
| 2021-06-24 |
Tarsus Pharmaceuticals, Inc. TARS |
S, Open-market sale | 10,000 disposed | 29.90 | 299,000.00 | Form 4, filing 0001213900-21-034310 | |
| 2021-06-23 |
Tarsus Pharmaceuticals, Inc. TARS |
S, Open-market sale | 37,980 disposed | 29.80 | 1,131,804.00 | Form 4, filing 0001213900-21-034310 | |
| 2021-06-22 |
Tarsus Pharmaceuticals, Inc. TARS |
S, Open-market sale | 110,000 disposed | 28.50 | 3,135,000.00 | Form 4, filing 0001213900-21-034298 | |
| 2021-06-21 |
Tarsus Pharmaceuticals, Inc. TARS |
S, Open-market sale | 91,620 disposed | 29.70 | 2,721,114.00 | Form 4, filing 0001213900-21-034298 | |
| 2021-04-14 |
Tarsus Pharmaceuticals, Inc. TARS |
S, Open-market sale | 400 disposed | 30.37 | 12,148.00 | Form 4, filing 0001213900-21-021965 | |
| 2021-03-23 |
Instil Bio, Inc. TIL |
P, Open-market purchase | 300,000 acquired | 20.00 | 6,000,000.00 | Form 4, filing 0001209191-21-023066 | |
| 2020-10-20 |
Tarsus Pharmaceuticals, Inc. TARS |
P, Open-market purchase | 250,000 acquired | 16.00 | 4,000,000.00 | Form 4, filing 0001209191-20-055423 | |
| 2020-07-21 |
ALX Oncology Holdings Inc ALXO |
P, Open-market purchase | 789,474 acquired | 19.00 | 15,000,006.00 | Form 4, filing 0000899243-20-019915 | |
| 2020-07-21 |
ALX Oncology Holdings Inc ALXO |
P, Open-market purchase | 185,526 acquired | 19.00 | 3,524,994.00 | Form 4, filing 0000899243-20-019915 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- P, Open-market purchase
- Open-market purchase
- S, Open-market sale
- Open-market sale
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. Vivo Capital IX, LLC, insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001750698
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6